Prophylactic Effectiveness of Coenzyme Q10 for Migraine in Adults: A Systematic Review and Meta-Analysis of Double-Blinded Randomized Clinical Trials
Abstract
We aimed to evaluate the influence of coenzyme Q10 alone (CoQ10) or in association with other nutraceuticals (CoQ10+) on the frequency, severity, duration of migraine attacks, and quality of life. We conducted a meta-analysis and a network meta-analysis (NMA) according to PRISMA 2020. We searched PubMed, Web of Science, Google Scholar, and Europe PMC for eligible studies up to January 2024. We used R software for pooled outcomes. This meta-analysis was registered in PROSPERO (CRD42024499733). Five studies were included, with a total of 326 individuals with confirmed migraine. CoQ10/CoQ10+ was shown to be associated with significant improvement in migraine frequency per month, and migraine duration and severity. NMA indicated that CoQ10 combined with L-carnitine appeared to be more effective than CoQ10 on migraine frequency and severity (SMD= -0.99 [95% CI: -1,68 to -0,29]; SMD= -3.05 [95% CI: -4.05 to -2.04], respectively). CoQ10 associated with L-carnitine yielded the greatest significant decrease in migraine duration compared with placebo; NMA revealed no significant difference between CoQ10, CoQ10 with multivitamin, and CoQ10 with L-carnitine. Our findings suggest that for optimal effectiveness, the use of CoQ10/CoQ10+ should be prolonged for at least 3 months. Using CoQ10 had a significant effect on the improvement of the quality of life of patients with migraine. Our meta-analysis suggested a beneficial effect of CoQ10/CoQ10+ for reducing monthly migraine frequency, severity, and duration, notably when it was associated with L-carnitine. Additionally, CoQ10 significantly improved the quality of life.
Amiri P, Kazeminasab S, Nejadghaderi SA, Mohammadinasab R, Pourfathi H, et al. Migraine: A review on its history, global epidemiology, risk factors, and comorbidities. Front Neurol 2022;12:800605.
Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, et al. The prevalence and disability burden of adult migraine in England and their relationships to age, sex and ethnicity. Cephalalgia 2003;23:519-527.
Wang Y, Wang Y, Yue G, Zhao Y. Energy metabolism disturbance in migraine: From a mitochondrial point of view. Front Physiol 2023;14:1133528.
Sazali S, Badrin S, Norhayati MN, Idris NS. Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine: A meta-analysis. BMJ Open 2021;11:e039358.
Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 2005;64:713-715.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Heal 2019;22:153-160.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 2010;1:97-111.
Van Aert RCM, Wicherts JM, van Assen MALM. Publication bias examined in meta-analyses from psychology and medicine: A meta-meta-analysis. PLoS One 2019;14:e0215052.
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, et al. What is “quality of evidence” and why is it important to clinicians? BMJ 2008;336:995-998.
Gaul C, Diener HC, Danesch U; Migravent® Study Group. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: A randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 2015;16:516.
Dahri M, Hashemilar M, Asghari-Jafarabadi M, Esfanjani A. Efficacy of coenzyme Q10 for the prevention of migraine in women: A randomized, double-blind, placebo-controlled study. Eur J Integr Med 2017;16:8-14.
Hajihashemi P, Askari G, Khorvash F, Reza Maracy M, Nourian M. The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. Cephalalgia 2019;39:648-654.
Parohan M, Sarraf P, Javanbakht MH, Foroushani AR, Ranji-Burachaloo S, et al. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. Nutr Neurosci 2021;24:317-326.
Zeng Z, Li Y, Lu S, Huang W, Di W. Efficacy of CoQ10 as supplementation for migraine: A meta-analysis. Acta Neurol Scand 2019;139:284-293.
Dahri M, Tarighat-Esfanjani A, Asghari-Jafarabadi M, Hashemilar M. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr Neurosci 2019;22:607-615.
Shoeibi A, Olfati N, Soltani Sabi M, Salehi M, Mali S, et al. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: An open-label, add-on, controlled trial. Acta Neurol Belg 2017;117:103-109.
Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011;31:897-905.
Rozen TD, Oshinsky ML, Gebeline CA, Bradley KC, Young WB, et al. Open-label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-141.
Parohan M, Sarraf P, Javanbakht MH, Ranji-Burachaloo S, Djalali M. Effect of coenzyme Q10 supplementation on clinical features of migraine: A systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Neurosci 2020;23:868-875.
Nattagh-Eshtivani E, Dahri M, Hashemilar M, Esfanjani A. The effect of Coenzyme Q10 supplementation on serum levels of lactate, pyruvate, matrix metalloproteinase 9 and nitric oxide in women with migraine. A double-blind, placebo, controlled randomized clinical trial. Eur J Integr Med 2018;21:70-76.
Arenas-Jal M, Suñé-Negre JM, García-Montoya E. Coenzyme Q10 supplementation: Efficacy, safety, and formulation challenges. Compr Rev Food Sci Food Saf 2020;19:574-594.
Gutierrez-Mariscal FM, Yubero-Serrano EM, Villalba JM, Lopez-Miranda J. Coenzyme Q10: From bench to clinic in aging diseases, a translational review. Crit Rev Food Sci Nutr 2019;59:2240-2257.
Al Saadi T, Assaf Y, Farwati M, Turkmani K, Al-Mouakeh A, et al. Coenzyme Q10 for heart failure. Cochrane Database Syst Rev 2021;2:CD008684.
López-Lluch G, Del Pozo-Cruz J, Sánchez-Cuesta A, Cortés-Rodríguez AB, Navas P. Bioavailability of coenzyme Q10 supplements depends on carrier lipids and solubilization. Nutrition 2019;57:133-140.
El-Hattab AW, Scaglia F. Disorders of carnitine biosynthesis and transport. Mol Genet Metab 2015;116:107-112.
Tauffenberger A, Fiumelli H, Almustafa S, Magistretti PJ. Lactate and pyruvate promote oxidative stress resistance through hormetic ROS signaling. Cell Death Dis 2019;10:653.
Hagen K, Brenner E, Linde M, Gravdahl GB, Tronvik EA, et al. Acetyl-l-carnitine versus placebo for migraine prophylaxis: A randomized, triple-blind, crossover study. Cephalalgia 2015;35:987-995.
| Files | ||
| Issue | Vol 10, No 3, 2025 | |
| Section | Research Article(s) | |
| DOI | https://doi.org/10.18502/tim.v10i3.19757 | |
| Keywords | ||
| Coenzyme Q10 L-Carnitine Migraine attack frequency Migraine attack duration Migraine attack severity Quality of life | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
